A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)

By:
On:
In: Trials

Condition:   Chronic Cluster Headache
Interventions:   Drug: Fremanezumab- A;   Drug: Fremanezumab- B;   Drug: Placebo
Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting – verified July 2017
Source: ClinicalTrials.gov Listing of Cluster Headache trials
The purpose of the current study is to evaluate the efficacy and safety of TEV-48125 (Fremanezumab), in the prevention of CCH in adult patients.